logo-loader
viewImugene Ltd

Imugene research published in prestigious journal titled Frontiers in Immunology

The research has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies.

Imugene Ltd - Imugenes'  research published in prestigious journal titled Frontiers in Immunology
Imugene is a privately held drug discovery and development company

Imugene Ltd’s (ASX:IMU) preclinical research to improve mimotope vaccines targeting checkpoint inhibitors has been accepted and published in the prestigious journal Frontiers in Immunology.

Ground-breaking research from Vienna identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies that bind specifically to immune cells expressing the PD1 biomarker.

The naturally produced antibodies block a protective mechanism on cancer cells and allows the immune system to destroy those cancer cells, as shown in animal models of breast cancer.

This research was conducted under the leadership of Imugene SAB member Professor Dr Ursula Wiedermann with Dr Joshua Tobias as lead author.

Transforming into multi-asset company

IMU managing director and CEO Leslie Chong said: “Development of this new immunotherapy expands our pipeline and further transforms Imugene into a multi-asset biopharmaceutical company.

“The concept of teaching and inducing the body to generate its own antibodies targeting PD1 expressing cells represents a paradigm shift in oncology and this is the first journal report of treating cancer by this method.

“The publication is a detailed study of the mechanism of action of active immunisation targeting immune checkpoint regulator PD1.

“The results validate and support the B cell ‘epitope’ contained in Imugene’s PD1-Vaxx, scheduled to commence a Phase 1 trial in 2020.”

B-cell cancer immunotherapy

Imugene’s PD1-Vaxx is a B-cell cancer immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction.

The primary objective of the phase 1 trial is to determine safety and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors. Efficacy, tolerability and immune response will also be measured.

Quick facts: Imugene Ltd

Price: 0.034 AUD

ASX:IMU
Market: ASX
Market Cap: $150.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 19/3/19

2 min read